Oral Cancer Drugs Deserve Parity
There have been some legislative efforts to bring parity to oral cancer drugs so that insurance companies treat them the same way as injectable cancer drugs.
The American Cancer Society takes a cautious approach to oral parity. Stephen Finan, senior director of policy for the American Cancer Society Cancer Action Network, said in an e-mail that the group is monitoring the issue "to better understand how health plans are handling coverage for both oral and injectable treatments -- specifically to make sure that affordability isn't challenged through increased premiums, stricter utilization management tools or exclusion of anti-cancer medications from formularies to contain costs."
Margaret Dick Tocknell is a reporter/editor with HealthLeaders Media.
- Nurse Ethics Comes to a Head at Guantanamo Bay
- Providers' Push to Consolidate Roils Payers
- In Lakeport, CA, a Population Health Laboratory is Born
- Transforming Decision Support and Reporting
- Insurers' listings of in-network doctors often out of date
- How to navigate big data in healthcare
- CMS Mulls Income-Adjusting MA Stars
- Opinion: What healthcare can learn from CHS data breach
- Costs of responding to Ebola adding up
- As Retail Clinics Surge, Quality Metrics MIA